01/27/23 8:30 AMOTC : BICX conferenceslow floatBioCorRx to Present at Sequire Biotechnology Conference on February 2ndBioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that LourdesRHEA-AIneutral
01/24/23 9:00 AMOTC : BICX managementlow floatBioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of DirectorsBioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced that Mr. Harsha Murthy was appointed to the Company’s Board ofRHEA-AIvery positive
01/19/23 8:30 AMOTC : BICX clinical triallow floatBioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disordervia NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced an update from the Phase I clinical trial of BICX104, an implantableRHEA-AIneutral
12/07/22 9:00 AMOTC : BICX partnershiplow floatBioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United StatesBioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has partnered with Government Plus LLC, a leading providerRHEA-AIpositive
11/22/22 9:00 AMOTC : BICX managementlow floatBioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that its board of directors has authorized the exploration of aRHEA-AIvery positive
11/15/22 9:00 AMOTC : BICX low floatBioCorRx Provides Business Update for the Third Quarter of 2022BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2022 andRHEA-AIneutral
10/13/22 8:30 AMOTC : BICX clinical triallow floatBioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disordervia NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the last subject has been enrolled in the Phase I clinical trialRHEA-AIneutral
09/06/22 8:30 AMOTC : BICX conferenceslow floatBioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conferencevia NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO, and Director of BioCorRx, will beRHEA-AIneutral
08/16/22 8:30 AMOTC : BICX low floatBioCorRx Provides Business Update for the Second Quarter of 2022via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 andRHEA-AIneutral
07/13/22 8:30 AMOTC : BICX conferenceslow floatBioCorRx to Participate in the Benzinga All Access Event on July 15thvia NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEORHEA-AIneutral